Request Sample Form

Name*:

Phone No.*:

Email*:

Service Intersted In:

Download Complete Report

Your Name*:

Email*:

Contact Number*:

Subject*:

Service Interested In* (required)

Your Requirment*:

Rozlytrek bags FDA approval

Roche has announced the US Food and Drug Administration (FDA) approval of Rozlytrek (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC).

August 16th, 2019|News|

Chlamydia Vaccine Could Become Reality After Successful Clinical Trial

A vaccine to protect against chlamydia is now a step closer to becoming reality after a pioneering clinical trial has found the treatment to be safe.

August 13th, 2019|News|

Rise of complex life could be explained by oddball microbe

Biologists have for the first time captured and grown an elusive type of microbe that is similar to those that might have given rise to all complex life on Earth.

August 9th, 2019|News|

Nano based vaccine for treating melanoma

Researchers have developed a novel nano-vaccine for melanoma, the most aggressive type of skin cancer. Their approach has so far proven effective in preventing the development of melanoma in mouse models and in treating primary tumors and metastases that result from melanoma.

 

 
August 6th, 2019|News|

Manipulating brain cells using smartphone by scientists

A team of scientists have invented a device that can control neural circuits using a tiny brain implant controlled by a smartphone. The device could speed up efforts to uncover brain diseases such as Parkinson’s, Alzheimer’s, addiction, depression, and pain.

 
August 5th, 2019|News|

Teijin Completes Acquisition of Renegade

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.

August 2nd, 2019|News|

FDA grants Opdivo combo Breakthrough Designation for melanoma

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for investigational agent bempegaldesleukin (NKTR-214) in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) for the treatment of patients with previously untreated unresectable or metastatic melanoma.

August 2nd, 2019|News|

Shares of Taco Bell owner Yum Brands jump as earnings top estimates

Yum Brands reported second-quarter earnings Thursday that beat Wall Street’s expectations, sending its shares up more than 6%.

August 1st, 2019|News|

Mississippi Lime Completes Acquisition of Southern Lime, Begins Integration of the Calera, Alabama based Business

a leading global supplier of high-calcium lime products and a portfolio company of HBM Holdings, today announced it has completed its acquisition of the Calera, Alabama lime business of Covia (NYSE: CVIA), operating historically as Southern Lime.

August 1st, 2019|News|

Nubeqa bags FDA green light

The US Food and Drug Administration (FDA) has approved Eli Lilly’s non-steroidal androgen receptor inhibitor (ARi), Nubeqa (darolutamide), for men with non-metastatic castration-resistant prostate cancer.

July 31st, 2019|News|